Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations i… Read more
Marinus Pharmaceuticals Inc (MRNS) - Net Assets
Latest net assets as of September 2024: $-66.74 Million USD
Based on the latest financial reports, Marinus Pharmaceuticals Inc (MRNS) has net assets worth $-66.74 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.62 Million) and total liabilities ($130.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-66.74 Million |
| % of Total Assets | -104.9% |
| Annual Growth Rate | 13.46% |
| 5-Year Change | -80.9% |
| 10-Year Change | -59.26% |
| Growth Volatility | 116.46 |
Marinus Pharmaceuticals Inc - Net Assets Trend (2012–2023)
This chart illustrates how Marinus Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Marinus Pharmaceuticals Inc (2012–2023)
The table below shows the annual net assets of Marinus Pharmaceuticals Inc from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $16.77 Million | -85.55% |
| 2022-12-31 | $116.00 Million | +116.88% |
| 2021-12-31 | $53.49 Million | -61.02% |
| 2020-12-31 | $137.20 Million | +56.32% |
| 2019-12-31 | $87.77 Million | +28.46% |
| 2018-12-31 | $68.33 Million | +17.79% |
| 2017-12-31 | $58.01 Million | +170.07% |
| 2016-12-31 | $21.48 Million | -54.22% |
| 2015-12-31 | $46.92 Million | +14.01% |
| 2014-12-31 | $41.15 Million | +335.12% |
| 2013-12-31 | $9.46 Million | +126.16% |
| 2012-12-31 | $4.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Marinus Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51569284000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $55.00K | 0.33% |
| Other Comprehensive Income | $-20.00K | -0.12% |
| Other Components | $588.66 Million | 3511.22% |
| Total Equity | $16.77 Million | 100.00% |
Marinus Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Marinus Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Celik Halat ve Tel Sanayi AS
IS:CELHA
|
$20.57 Million |
|
LPS Brasil - Consultoria de Imóveis S.A
SA:LPSB3
|
$20.57 Million |
|
HEALTH NET
F:HNT
|
$20.58 Million |
|
Titania Holding AB Series B
ST:TITA-B
|
$20.59 Million |
|
Metallic Minerals Corp
OTCQB:MMNGF
|
$20.56 Million |
|
Alto Metals Ltd
AU:AME
|
$20.54 Million |
|
Cayenne Entertainment Technology Co. Ltd.
TWO:4946
|
$20.54 Million |
|
Solid State System Co. Ltd.
TWO:3259
|
$20.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Marinus Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 116,000,000 to 16,765,000, a change of -99,235,000 (-85.5%).
- Net loss of 141,405,000 reduced equity.
- New share issuances of 90,397,000 increased equity.
- Other comprehensive income decreased equity by 20,000.
- Other factors decreased equity by 48,207,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-141.41 Million | -843.45% |
| Share Issuances | $90.40 Million | +539.2% |
| Other Comprehensive Income | $-20.00K | -0.12% |
| Other Changes | $-48.21 Million | -287.55% |
| Total Change | $- | -85.55% |
Book Value vs Market Value Analysis
This analysis compares Marinus Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.76x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.27x to 1.76x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $2.07 | $0.55 | x |
| 2013-12-31 | $4.69 | $0.55 | x |
| 2014-12-31 | $26.76 | $0.55 | x |
| 2015-12-31 | $12.58 | $0.55 | x |
| 2016-12-31 | $4.41 | $0.55 | x |
| 2017-12-31 | $9.86 | $0.55 | x |
| 2018-12-31 | $6.68 | $0.55 | x |
| 2019-12-31 | $6.44 | $0.55 | x |
| 2020-12-31 | $5.03 | $0.55 | x |
| 2021-12-31 | $1.46 | $0.55 | x |
| 2022-12-31 | $2.97 | $0.55 | x |
| 2023-12-31 | $0.31 | $0.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Marinus Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -843.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -456.31%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 10.19x
- Recent ROE (-843.45%) is below the historical average (-129.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -33.68% | -1408.55% | 0.01x | 2.08x | $-1.83 Million |
| 2013 | -55.72% | 0.00% | 0.00x | 1.25x | $-6.22 Million |
| 2014 | -26.32% | 0.00% | 0.00x | 1.22x | $-14.95 Million |
| 2015 | -52.96% | 0.00% | 0.00x | 1.27x | $-29.54 Million |
| 2016 | -133.35% | 0.00% | 0.00x | 1.46x | $-30.79 Million |
| 2017 | -32.58% | 0.00% | 0.00x | 1.05x | $-24.70 Million |
| 2018 | -53.75% | 0.00% | 0.00x | 1.10x | $-43.56 Million |
| 2019 | -61.26% | 0.00% | 0.00x | 1.13x | $-62.54 Million |
| 2020 | -48.57% | -3879.05% | 0.01x | 1.10x | $-80.36 Million |
| 2021 | -190.07% | -662.50% | 0.11x | 2.56x | $-107.01 Million |
| 2022 | -17.08% | -77.78% | 0.10x | 2.24x | $-31.42 Million |
| 2023 | -843.45% | -456.31% | 0.18x | 10.19x | $-143.08 Million |
Industry Comparison
This section compares Marinus Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Marinus Pharmaceuticals Inc (MRNS) | $-66.74 Million | -33.68% | N/A | $20.57 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |